Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI (SAN)

Delayed Quote. Delayed  - 08/26 05:35:10 pm
69.35 EUR   +1.14%
08/25 DÉPAKINE : 14 300 femmes enceintes seront indemnisées
08/24 SANOFI : Haiti Impact Trip Provides Eye-Opening Experience for Stop ..
08/22 MEDIVATION : Pfizer propose 14 milliards de dollars pour racheter Me..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

SANOFI : Combined General Shareholder Meeting of May 4, 2012

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/04/2012 | 07:35pm CEST
PRESS RELEASE Combined General Shareholder Meeting of May 4, 2012

? Shareholder approval of the corporate and consolidated financial statements for 2011

? Dividend of ?2.65 per share payable as of May 15, 2012

? Nomination of a new director

? Partial renewal of the Board of Directors

Paris, France - May 4, 2012 - Sanofi (EURONEXT : SAN et NYSE : SNY) announced its Combined General Shareholder Meeting was held today at the Palais des Congrès in Paris. All resolutions were adopted by its shareholders.

During the meeting, shareholders approved, among other resolutions, the corporate and consolidated financial statements for the year 2011. At the General Meeting, shareholders decided the distribution of a dividend in the amount of ?2.65 per share that will be detached on Euronext Paris on May 10, 2012 with payment as of May 15, 2012.
The General Meeting also approved the appointment of Mr. Laurent Attal as a director for a term of four years, i.e., until the General Meeting called to approve the financial statements for the year
2015. Finally, Mr. Uwe Bicker, Mr. Jean-René Fourtou, Ms. Claudie Haigneré, Ms. Carole Piwnica and Mr. Klaus Pohle have each been reappointed for a term of four years.
After the Shareholder Meeting, the Board of Directors is comprised as follows:

? Serge Weinberg, Chairman of the Board of Directors

? Christopher Viehbacher, Chief Executive Officer

? Laurent Attal

? Uwe Bicker

? Robert Castaigne

? Thierry Desmarest

? Lord Douro

? Jean-René Fourtou

? Claudie Haigneré

? Igor Landau

? Suet-Fern Lee

? Christian Mulliez

? Carole Piwnica

? Klaus Pohle

? Gérard Van Kemmel

During the meeting, the shareholders approved the appointment of statutory and deputy auditors. The shareholders additionally ratified the move of the registered headquarters of Sanofi to 54, rue La Boétie, 75008 Paris. During the Board of Directors session following the meeting, Mr. Klaus Pohle was renewed as Chairman of the Audit Committee.

1/2

The voting results will be available on the company's website (www.sanofi.com) in the coming days.
The audiocast of the Combined General Shareholder Meeting is available on the Company's website (www.sanofi.com).

About Sanofi

Sanofi, a global and diversified healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Contacts:

Media Relations Investor Relations

Jean-Marc Podvin Sébastien Martel

+ (33) 1 53 77 46 46 + (33) 1 53 77 45 45 mr@sanofi.com ir@sanofi.com

2/2

distributed by
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on SANOFI
08/25 SANOFI : Researchers from Sanofi Aventis Report Findings in Hepatic Encephalopat..
08/25 DÉPAKINE : 14 300 femmes enceintes seront indemnisées
08/24 SANOFI : Haiti Impact Trip Provides Eye-Opening Experience for Stop Hunger Now P..
08/22 MEDIVATION : Pfizer propose 14 milliards de dollars pour racheter Medivation
08/22 Pfizer to buy cancer drugmaker Medivation for $14 billion
08/22 Pfizer to buy Medivation and boost cancer drug portfolio
08/22 SANOFI : Provides Update on New Drug Application for Investigational Once-Daily ..
08/22 PHARMA MAJOR PFIZER OUTBIDS SANOFI T : Reports
08/22DJPfizer Near $14 Billion Deal for Biotech -- WSJ
08/21 SANOFI : Research center in Oro Valley looks to grow after spinoff from Sanofi
More news
Sector news : Pharmaceuticals - NEC
12:53a Stada shareholder AOC pushes through board reshuffle
12:43a ABBOTT LABORATORIES : Whiplashed investors stay skittish about St. Jude
08/26DJST JUDE MEDICAL : . Jude Denies Claims in Muddy Waters Report
08/26 MUDDY WATERS SAYS ST. JUDE SHARES CO : Cnbc
08/26DJALERE : Sues Abbott to Force Merger -- 2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
08/26 FDA recommends Zika screening of blood components in all states and territori..
08/26 Updating My Price Target On Pfizer
08/26 What's Going On At Mylan?
08/26 Don't Fear The Fed - Cramer's Mad Money (8/25/16)
08/25 Shocked! Mylan, Biotechs Swoon After Hillary's Statement
Advertisement
Financials (€)
Sales 2016 36 960 M
EBIT 2016 9 286 M
Net income 2016 5 309 M
Debt 2016 5 008 M
Yield 2016 4,25%
P/E ratio 2016 15,83
P/E ratio 2017 14,42
EV / Sales 2016 2,55x
EV / Sales 2017 2,55x
Capitalization 89 393 M
More Financials
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | SAN | FR0000120578 | 4-Traders
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 23
Average target price 84,5 €
Spread / Average Target 22%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Olivier Brandicourt Chief Executive Officer & Director
Serge Weinberg Chairman
JÚr˘me Contamine Chief Financial Officer & EVP-Finance
Elias E. Zerhouni President-Global Research & Development
Yong-Jun Liu Head-Global Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI-11.77%100 075
JOHNSON & JOHNSON15.89%325 679
ROCHE HOLDING LTD.-11.47%214 671
PFIZER INC.7.87%211 206
NOVARTIS AG-9.62%210 234
ASTRAZENECA PLC7.33%173 797
More Results